Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.

Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.

Show other versions (1)

<h4>Background</h4>Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily c...

Full description

Bibliographic Details
Main Authors:	Yuko Kanbayashi, Mayumi Shimizu, Yuichi Ishizuka, Shohei Sawa, Katsushige Yabe, Mayako Uchida
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0278823

Similar Items

Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis
by: Yuko Kanbayashi, et al.
Published: (2022-01-01)

Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
by: Joelle BouSaba, et al.
Published: (2022-04-01)

Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
by: Iwao Osaka, et al.
Published: (2019-07-01)

A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients
by: Hisao Imai, et al.
Published: (2022-08-01)

Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial
by: Anna Ozaki, et al.
Published: (2022-04-01)

Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives
by: Martin E. Hale, et al.
Published: (2021-07-01)

A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer
by: Teruhiko Kamiya, et al.
Published: (2023-03-01)

Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
by: Saito Y, et al.
Published: (2018-12-01)

Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies
by: Camilleri M, et al.
Published: (2021-07-01)

Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study
by: Hiromi Nishiba, et al.
Published: (2022-05-01)

Naldemedine is associated with earlier defecation in critically ill patients with opioid-induced constipation: A retrospective, single-center cohort study
by: Seiya Nishiyama, et al.
Published: (2024-01-01)

Naldemedine is associated with earlier defecation in critically ill patients with opioid-induced constipation: A retrospective, single-center cohort study.
by: Seiya Nishiyama, et al.
Published: (2024-01-01)

Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study
by: Eriko Hiruta, et al.
Published: (2021-11-01)

Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol
by: Takahiro Higashibata, et al.
Published: (2022-10-01)

Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness
by: Mehta N, et al.
Published: (2023-10-01)

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study
by: Anna Ozaki, et al.
Published: (2020-06-01)

Naldemedine: A New Option for OIBD
by: Coluzzi F, et al.
Published: (2020-05-01)

Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study
by: Yusuke Takagi, et al.
Published: (2020-01-01)

Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database
by: Yuko Kanbayashi, et al.
Published: (2022-09-01)

Methylnaltrexone in the treatment of opioid-induced constipation
by: Beverley Greenwood-Van Meerveld, et al.
Published: (2008-12-01)

Progress on Drug Therapy for Opioid-induced Constipation
by: Jiachun NI, Zengjin CAI, Qiong JIANG, Haibo LAN, Xiangdong YANG, Wenbin FAN
Published: (2022-04-01)

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
by: Yuko Kanbayashi, et al.
Published: (2023-05-01)

Impact of opioid-induced constipation on opioid substitution therapy management: the patient perspective
by: Fabio Lugoboni, et al.
Published: (2021-10-01)

Insights into the Current and Possible Future Use of Opioid Antagonists in Relation to Opioid-Induced Constipation and Dysbiosis
by: Nariman Essmat, et al.
Published: (2023-11-01)

Opioid-Induced Constipation in Advanced Illness: Safety and Efficacy of Methylnaltrexone Bromide
by: S. Bader, et al.
Published: (2011-01-01)

Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities
by: Alfred D. Nelson, et al.
Published: (2015-07-01)

Common Clinical Practice for Opioid-Induced Constipation: A Physician Survey
by: Coluzzi F, et al.
Published: (2021-07-01)

Delphi consensus on strategies in the management of opioid-induced constipation in cancer patients
by: Regina Gironés Sarrió, et al.
Published: (2021-01-01)

Patient and provider differences in the treatment of opioid-induced constipation: a qualitative study
by: Michelle S. Keller, et al.
Published: (2019-11-01)

Optimal treatment of opioid induced constipation in daily clinical practice – an observational study
by: Elisabeth C. W. Neefjes, et al.
Published: (2019-03-01)

Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
by: Rauck RL, et al.
Published: (2018-12-01)

The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety
by: Pergolizzi JV Jr, et al.
Published: (2020-03-01)

Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation
by: David Farchadi, MD, MS, et al.
Published: (2023-01-01)

Itopride increases the effectiveness of the management of opioid-induced constipation in palliative care patients: an observational non-interventional study
by: Tomasz Dzierżanowski, et al.
Published: (2019-07-01)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
by: Webster LR, et al.
Published: (2015-10-01)

Peripheral Opioid Receptor Antagonists for Opioid-Induced Constipation: A Primer on Pharmacokinetic Variabilities with a Focus on Drug Interactions
by: Gudin J, et al.
Published: (2020-02-01)

Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose
by: Chamberlain BH, et al.
Published: (2023-07-01)

Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem
by: Yoon SC, et al.
Published: (2017-07-01)

Prokinetic effects of diatrizoate meglumine (Gastrografin®) in a zebrafish for opioid-induced constipation model
by: Dongwoo Kim, et al.
Published: (2021-10-01)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum]
by: Webster LR, et al.
Published: (2018-06-01)